Leukogene Therapeutics Inc.
February 11, 2025
Plymouth
Oncology
Leukogene is oncology focused company with mission to deliver innovative therapies with emphasis on immunologically “cold” tumors. Leukogene's proprietary MHCII targeted immunotherapy platform (M2T™) actively triggers robust, tumor antigen specific immune response. Our lead programs are in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and pancreatic ductal adenocarcinoma (PDAC) with preclinical proof of concept in relevant models.
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}